ANXA9 expression was also associated with a poor prognosis in ovarian cancer and resistance to cisplatin in vitro and in vivo, posing ANXA9 as an interesting candidate for targeted therapies to overcome cisplatin-resistant cancers (Kou et al., 2021). This evidence concerns the gene ANXA9 and ovarian carcinoma.